IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Lifted by Marshall Financial Group LLC

Marshall Financial Group LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,286 shares of the company’s stock after acquiring an additional 290 shares during the quarter. Marshall Financial Group LLC’s holdings in IDEXX Laboratories were worth $960,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Fiera Capital Corp raised its holdings in shares of IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company’s stock worth $58,377,000 after purchasing an additional 15,463 shares in the last quarter. Blue Zone Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $3,958,000. Villere ST Denis J & Co. LLC increased its holdings in shares of IDEXX Laboratories by 2.6% in the fourth quarter. Villere ST Denis J & Co. LLC now owns 62,442 shares of the company’s stock valued at $25,816,000 after buying an additional 1,556 shares in the last quarter. Alberta Investment Management Corp lifted its position in shares of IDEXX Laboratories by 25.3% during the 4th quarter. Alberta Investment Management Corp now owns 10,900 shares of the company’s stock valued at $4,506,000 after acquiring an additional 2,200 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $2,681,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on IDXX shares. Leerink Partners lifted their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a research report on Monday, May 19th. Finally, Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $546.00.

IDEXX Laboratories Stock Performance

IDXX stock opened at $526.92 on Friday. The firm has a 50 day simple moving average of $469.88 and a 200 day simple moving average of $443.57. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $537.00. The stock has a market cap of $42.38 billion, a P/E ratio of 49.38, a P/E/G ratio of 3.41 and a beta of 1.55. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the firm earned $2.71 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the business’s stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total value of $537,372.04. Following the transaction, the director now owns 262 shares in the company, valued at $134,599.88. The trade was a 79.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.